JP5406725B2 - タンパク質キナーゼ阻害剤として有用な化合物 - Google Patents

タンパク質キナーゼ阻害剤として有用な化合物 Download PDF

Info

Publication number
JP5406725B2
JP5406725B2 JP2009541404A JP2009541404A JP5406725B2 JP 5406725 B2 JP5406725 B2 JP 5406725B2 JP 2009541404 A JP2009541404 A JP 2009541404A JP 2009541404 A JP2009541404 A JP 2009541404A JP 5406725 B2 JP5406725 B2 JP 5406725B2
Authority
JP
Japan
Prior art keywords
aliphatic
cancer
compound
halo
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513285A (ja
JP2010513285A5 (enExample
Inventor
ジャン・ダミアン・シャリエール
デイビッド・ケイ
ロナルト・クネフテル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2010513285A publication Critical patent/JP2010513285A/ja
Publication of JP2010513285A5 publication Critical patent/JP2010513285A5/ja
Application granted granted Critical
Publication of JP5406725B2 publication Critical patent/JP5406725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009541404A 2006-12-14 2007-12-14 タンパク質キナーゼ阻害剤として有用な化合物 Expired - Fee Related JP5406725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87487806P 2006-12-14 2006-12-14
US60/874,878 2006-12-14
PCT/US2007/025688 WO2008076392A2 (en) 2006-12-14 2007-12-14 Compounds useful as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2010513285A JP2010513285A (ja) 2010-04-30
JP2010513285A5 JP2010513285A5 (enExample) 2011-04-14
JP5406725B2 true JP5406725B2 (ja) 2014-02-05

Family

ID=39323721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541404A Expired - Fee Related JP5406725B2 (ja) 2006-12-14 2007-12-14 タンパク質キナーゼ阻害剤として有用な化合物

Country Status (12)

Country Link
US (2) US8129387B2 (enExample)
EP (1) EP2102210B1 (enExample)
JP (1) JP5406725B2 (enExample)
CN (1) CN101646671A (enExample)
AT (1) ATE497961T1 (enExample)
AU (1) AU2007334379B2 (enExample)
CA (1) CA2672612A1 (enExample)
DE (1) DE602007012473D1 (enExample)
ES (1) ES2359467T3 (enExample)
MX (1) MX2009006345A (enExample)
NZ (1) NZ577638A (enExample)
WO (1) WO2008076392A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453548C2 (ru) 2006-01-17 2012-06-20 Вертекс Фармасьютикалз Инкорпорейтед Азаиндолы, полезные в качестве ингибиторов янус-киназ
JP2011515072A (ja) * 2008-02-13 2011-05-19 エラン ファーマ インターナショナル リミテッド α−シヌクレインキナーゼ
CN102076690A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
AU2009271663B2 (en) 2008-06-23 2014-04-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
TWI483941B (zh) 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
SG181908A1 (en) * 2009-12-23 2012-08-30 Elan Pharm Inc Pteridinones as inhibitors of polo-like kinase
BR112013008526A2 (pt) * 2010-10-08 2016-07-12 Elan Pharm Inc inibidores de quinase do tipo polo
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
WO2013006634A2 (en) 2011-07-05 2013-01-10 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6523267B2 (ja) * 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
SMT201900450T1 (it) 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
MX2018011792A (es) 2016-03-28 2019-07-04 Incyte Corp Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam).
EP3687996B1 (en) 2017-09-27 2021-11-03 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
DK3813800T3 (da) 2018-06-29 2025-06-02 Incyte Corp Formuleringer af en axl/mer-hæmmer
CN111217815B (zh) * 2018-11-27 2021-06-18 沈阳药科大学 含有喋啶酮骨架的化合物及其制备方法和应用
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
CN101200457A (zh) * 2003-02-26 2008-06-18 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
BRPI0718120A2 (pt) 2006-10-25 2013-11-12 Chroma Therapeutics Ltd Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
US8541437B2 (en) 2007-04-05 2013-09-24 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for the production and use thereof

Also Published As

Publication number Publication date
CN101646671A (zh) 2010-02-10
AU2007334379B2 (en) 2013-04-18
ES2359467T3 (es) 2011-05-23
NZ577638A (en) 2012-03-30
EP2102210B1 (en) 2011-02-09
ATE497961T1 (de) 2011-02-15
US8129387B2 (en) 2012-03-06
AU2007334379A1 (en) 2008-06-26
WO2008076392A2 (en) 2008-06-26
EP2102210A2 (en) 2009-09-23
MX2009006345A (es) 2009-06-23
CA2672612A1 (en) 2008-06-26
US20120122879A1 (en) 2012-05-17
US8557818B2 (en) 2013-10-15
DE602007012473D1 (de) 2011-03-24
JP2010513285A (ja) 2010-04-30
US20100099686A1 (en) 2010-04-22
WO2008076392A3 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
JP5406725B2 (ja) タンパク質キナーゼ阻害剤として有用な化合物
JP5313875B2 (ja) 増殖性疾患の処置のためのタンパク質キナーゼｐｌｋ１の阻害剤として有用な４，５−ジヒドロ−［１，２，４］トリアゾロ［４，３−ｆ］プテリジン
JP5634990B2 (ja) タンパク質キナーゼ阻害剤
JP5380447B2 (ja) 増殖性疾患の処置のための、ヒトタンパク質キナーゼｐｌｋ１ないしｐｌｋ４の阻害剤としての４−（９−（３，３−ジフルオロシクロペンチル）−５，７，７−トリメチル−６−オキソ−６，７，８，９−テトラヒドロ−５ｈ−ピリミド［４，５−ｂ［１，４］ジアゼパン−２−イルアミノ］−３−メトキシベンザミド誘導体
JP5869338B2 (ja) タンパク質キナーゼ阻害剤
JP2009533452A (ja) タンパク質キナーゼの阻害剤として有用なチオフェン−カルボキサミド
JP2009538309A (ja) プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
JP2009528991A (ja) プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン
US8481578B2 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009523822A (ja) プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
US7838517B2 (en) Compounds useful as protein kinase inhibitors
JP2009515984A (ja) キナーゼ阻害剤として有用なアザインダゾール
HK1130788A (en) Thiophene-carboxamides useful as inhibitors of protein kinases
HK1141512A (en) Compounds useful as protein kinase inhibitors
HK1137013A (en) Compounds useful as protein kinase inhibitors
HK1134285A (en) Thiophene-carboxamides useful as inhibitors or protein kinases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131101

LAPS Cancellation because of no payment of annual fees